Gene mutations that lower heart risks may help develop new drugs
Washington: Researchers have shown that people with variation in a gene that inhibits a specific protein in the blood - apolipoprotein C3 - have a significantly lower level of normal blood lipids than people without this gene variation.
Furthermore, the same individuals also have a 41 per cent lower risk of arteriosclerosis.
The research is highly relevant as at least one pharmaceutical company has a drug in the pipeline which inhibits precisely apolipoprotein C3, says Anne Tybjaerg-Hansen, Chief Physician at Rigshospitalet and Clinical Professor at the Faculty of Health and Medical Sciences, University of Copenhagen.
The scientific results are based on two of the world's largest population studies, the Copenhagen City Heart Study and the Copenhagen General Population Study, with a total 75,725 participants who were followed for 34 years.
By using genetic studies that mimic medical inhibition of apolipoprotein C3, we have demonstrated that the protein plays an important role in lowering the level of normal blood lipids and thus the risk of cardiovascular disease. People with lifelong hereditary inhibition of the protein have very low blood lipid levels (less than 1 mmol per litre of blood) as well as a significantly reduced risk of cardiovascular disease, says Anne Tybjaerg-Hansen.
The study is published in New England Journal of Medicine.
More from India
More from World
More from Sports
More from Entertaiment
- Coal scam: Court orders framing of charges against Naveen Jindal, others
- It's actually shocking! Three monks get involved in brawl at Buddhist temple in China - Watch
- ICICI net plunges 87% to over 11-year low as NPA provision soars
- Geologists discover earth's oldest piece of rock!
- Baaghi movie review: Tiger Shroff and Shraddha Kapoor's action-packed performances fail to make an impression